INASNACCINASNACC

Jurnal neuroanestesi indonesiaJurnal neuroanestesi indonesia

Herpes simplex viruses (HSV), including HSV-1 and HSV-2, are neurotropic viruses capable of establishing lifelong latency in sensory ganglia and reactivating under various triggers, including traumatic brain injury (TBI). TBI induces secondary injury cascades such as neuroinflammation, excitotoxicity, and blood-brain barrier disruption, which create a conducive environment for HSV reactivation. The reactivation of HSV after TBI, particularly HSV-1 and HSV-2, can lead to significant neurological consequences, including encephalitis, cognitive decline, and the development of neurodegenerative diseases like Alzheimers disease and Chronic Traumatic Encephalopathy. Current therapeutic approaches focus on antiviral agents like acyclovir and valacyclovir, which manage acute HSV infection but are less effective in preventing long-term neurological damage. Emerging research highlights the potential of anti-inflammatory and neuroprotective strategies to complement antiviral therapies, aiming to reduce the neuronal damage caused by viral reactivation and inflammation. However, gaps remain in understanding the precise mechanisms linking TBI-induced neuroinflammation to HSV reactivation and its long-term impact on neurological health. This review synthesizes the current literature on the pathophysiology of HSV reactivation following TBI, and their contributions to acute and chronic neurological outcomes.

In conclusion, the reactivation of HSV following TBI presents significant challenges in both acute and chronic neurological outcomes.Neuroinflammation and immune dysregulation, which are exacerbated by TBI, play crucial roles in facilitating HSV reactivation and subsequent neurodegenerative processes such as AD and CTE.Although emerging research points to the potential of novel therapies including immunomodulatory treatments and vaccines targeting HSV latency, several gaps of the precise mechanisms linking TBI to HSV reactivation remains undiscovered.Further research is essential to uncover these mechanisms and develop effective treatments to mitigate both the acute and long-term neurological consequences of HSV reactivation after TBI.

Penelitian lebih lanjut diperlukan untuk mengurai mekanisme pasti yang menghubungkan cedera otak traumatis (TBI) dengan reaktivasi virus herpes simpleks (HSV), terutama dalam konteks disfungsi kekebalan tubuh. Sebagai contoh, studi prospektif yang melibatkan pemantauan biomarker inflamasi dan viral load pada pasien TBI dapat membantu mengidentifikasi jendela waktu optimal untuk intervensi antivirus dan neuroprotektif. Selain itu, penelitian yang berfokus pada pengembangan vaksin yang secara khusus menargetkan pencegahan infeksi HSV atau mengurangi kemampuannya untuk memasuki keadaan laten akan sangat berharga. Terakhir, eksplorasi terapi yang ditargetkan pada reservoir viral laten, seperti ganglion trigeminal, dapat membantu menghilangkan virus atau mencegah reaktivasi setelah trauma, membuka jalan bagi strategi pengobatan yang lebih efektif dan personal.

  1. Simultaneous VZV and HSV-1 Reactivation after Minor Head Injury | European Journal of Case Reports in... ejcrim.com/index.php/EJCRIM/article/view/1746Simultaneous VZV and HSV 1 Reactivation after Minor Head Injury European Journal of Case Reports in ejcrim index php EJCRIM article view 1746
  2. Association of APOE Genotypes and Chronic Traumatic Encephalopathy | Neurogenetics | JAMA Neurology |... doi.org/10.1001/jamaneurol.2022.1634Association of APOE Genotypes and Chronic Traumatic Encephalopathy Neurogenetics JAMA Neurology doi 10 1001 jamaneurol 2022 1634
  3. Repetitive injury induces phenotypes associated with Alzheimer’s disease by reactivating HSV-1... doi.org/10.1126/scisignal.ado6430Repetitive injury induces phenotypes associated with AlzheimerAos disease by reactivating HSV 1 doi 10 1126 scisignal ado6430
Read online
File size217.82 KB
Pages6
DMCAReport

Related /

ads-block-test